Bid/Ask spread is ridiculous. Shorting the hell out of it from 21.75
FDA approval expected any day - the stock price should triple on the announcement.
The Hep C market is huge - over 60M pap smear tests are taken annually in the US.
GTHP's biophotonic cervical cancer scan is noninvasive, more accurate and produces instant test results.
Why buy an overbloated IPO of an unproven biotech years away from approval?
GTHP is at a market cap of $20M and days away from approval.
The scan was recently approved in Canada, Mexico, EU, Asia.....
International sales are ramping up - see the recent news on orders from China, Indonesia, Kenya.......
Short squeeze? 5% above last week's high. Maybe some big investors accumulation shares. I don't own them.
Never mind......I found the information
Lead Underwriter: JP Morgan, Citigroup
Co-Managers: Williams Blair, BMO Capital Markets
As mentioned in the Week Ahead blog post, the prior 12 J.P. Morgan-led biotechs average over 200% gains.
Sentiment: Strong Buy
Do you know the three analysts that combined have come up with the $76 Target price for this stock?
Charts don't look under 21.60? Any idea what with the selling pressure on this stock for the past 2 weeks?
Sector had a lot of pressure recently - and end of 2nd qtr is coming up. Bio see saw. - IMHO you will see over 20's again sooner rather than later. 06.26 GOVERN YOURSELF ACCORDINGLY